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Summary 
Genetic and epigenetic alterations contribute to the biological and clinical 
characteristics of myelodysplastic syndromes (MDS), but a role for socioeconomic 
environment remains unclear.  Here, socioeconomic status (SES) for 283 MDS 
patients was estimated using the Scottish Index of Multiple Deprivation tool.  Indices 
were assigned to quintile categorical indicators ranked from SES1 (lowest) to SES5 
(highest).  Clinicopathological features and outcomes between SES quintiles 
containing 15%, 20%, 19%, 30% and 16% of patients were compared.  Prognostic 
scores identified lower-risk MDS in 82% of patients, with higher-risk disease in 18%.  
SES quintiles did not associate with age, gender, cytogenetics, IPSS, or in sub-
analysis (n=95), driver mutations.  The odds ratio of a diagnosis of RA was greater 
than other MDS sub-types in SES5 (OR 1.9, p=0.024).  Most patients (91%) 
exclusively received supportive care.  SES did not associate with leukaemic-
transformation or the cause of death.  Cox regression models confirmed male 
gender (p<0.05), disease-risk (p<0.0001) and age (p<0.01) as independent 
predictors of leukaemia-free survival, with leukaemic-transformation an additional 
determinant of overall survival (p=0.07).  Thus, if access to healthcare is equitable, 
SES does not determine disease biology or survival in MDS patients receiving 
supportive treatment; whether outcomes following disease-modifying therapies are 
influenced by SES requires additional studies. 
 
Key words: Socioeconomic status, MDS, IPSS, outcomes, healthcare, genomic 
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Introduction 
Myelodysplastic syndromes (MDS) are disorders characterised by different levels of 
bone marrow failure, dysplasia affecting one or more haemopoietic cell lineages and 
a variable propensity for transformation to acute myeloid leukaemia (AML) (Nimer et 
al, 2008).  Over the last 40 years, a number of studies have enhanced our 
understanding of the biology of MDS and increased the accuracy of clinical 
prognostication (Platzbecker, 2015).  Earlier studies focussed on morphological 
(Bennett et al, 1982) and cytogenetic characteristics of MDS (Vardiman et al, 2002), 
but the advent of molecular sequencing techniques has helped identify acquired 
gene mutations in majority of MDS patients, with functional clustering that appears to 
be clinically relevant (Papaemmanuil et al, 2013; Itzykson et al, 2013).  Thus, driver 
mutations in haemopoietic stem cells contributing to specific sub-types of MDS have 
been identified, with the acquisition of additional mutations within this cellular 
compartment or downstream progenitors associating with transformation to AML.  In 
addition, epigenomic deregulation is being increasingly recognised in the 
pathogenesis of MDS (Itzykson et al, 2013; Itzykson & Fenaux, 2014).  The 
improved understanding of the biological characteristics of MDS is now enabling 
therapies which result in haematological improvement (reviewed in Garcia-Manero, 
2014) or prolong survival in subsets of patients (Fenaux et al, 2009). 
Despite the plethora of studies investigating genetic and epigenetic changes 
in MDS, a possible role for environmental factors in altering disease phenotype 
and/or influencing outcomes has been less well investigated.  Whether phenotypic 
characteristics and genomic alterations observed in MDS, commonly used for 
prognostication, are influenced by patient socioeconomic status (SES) is therefore 
unclear.  A role for the environment in influencing leukaemogenesis has been 
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suggested by the differences in the incidence of radiation-induced AML in genetically 
susceptible mice housed under different conditions (Walburg et al, 1968).  In these 
animal models, a pro-inflammatory ‘by-stander’ cell response to radiation creates an 
in vivo microenvironment favouring AML development (Mukherjee et al, 2014).  If 
inflammation were similarly important for the development of de novo MDS and AML 
in humans, SES could be an important contributor to clonal instability since DNA 
methylation profiling has suggested increased pro-inflammatory gene activity in 
individuals from lower socioeconomic backgrounds (Stringhini et al, 2015).  Support 
for an SES-associated effect on disease biology comes from the observation that 
mutations in the tumour suppressor gene TP53 in breast cancer are over-
represented in women with severe socioeconomic deprivation (Baker et al, 2010; 
Starks et al, 2013). 
Whether SES can alter outcome trajectories in MDS patients has not been 
extensively studied.  In patients with solid organ and other haematological neoplasia 
differences in time to diagnosis, access to clinical care or trials and comorbidity 
between patients that are SES-dependent are known to affect survival (Kolahdooz et 
al, 2014; Munro, 2005; Roberts et al, 2015; Rutherford et al, 2013).  For example, 
the lower incidence of childhood acute lymphoblastic leukaemia across levels of 
increasing relative deprivation could reflect under-diagnosis in lower socioeconomic 
communities (Kroll et al, 2012; Lightfoot et al, 2012), and the mortality in AML and 
myeloma appears to be reduced in higher SES groups in some studies (Kristinsson 
et al, 2009).  In MDS, studies investigating the effects of SES on outcomes (Wang et 
al, 2009; England et al, 2013) have yielded conflicting conclusions, possibly due to 
differences in healthcare funding or organisational structure of healthcare services.  
Studies on patients treated within the National Health Service (NHS) in the United 
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Kingdom are relatively less likely to be confounded by these variables since the NHS 
is free at the point-of-delivery and based on clinical need and not means-tested.  In 
addition, the delivery of secondary health care by a single treatment centre to all 
patients within the defined catchment area reduces patient selection bias in single-
institution studies.  These advantages lead us to investigate the effects of SES on 
clinic-pathological disease characteristics and treatment outcomes including cause 
of death in MDS patients within NHS Tayside that serves a population of 400,000. 
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Methods 
 
Patients 
Adults diagnosed with MDS including non-proliferative chronic myelomonocytic 
leukaemia (CMML) between 1996-2012 were identified from the Tayside MDS 
Registry that contains relevant information on patients diagnosed and managed in 
NHS Tayside.  This Registry has been established with approval from the Tayside 
Medical Research Ethics Committee.  Patients with incomplete datasets and those 
with refractory anaemia and excess of blasts in transformation (RAEB-t) were 
excluded.  Patient demographics, date of diagnosis, morphological MDS sub-type 
(FAB or WHO), karyotype, IPSS score (Greenberg et al, 1997), AML transformation 
and date of last follow-up or death were abstracted from the Registry.  For 
acquisition of additional patient data, Caldicott Guardian approval was obtained in 
compliance with local information governance regulations. 
Results of targeted gene sequencing reported previously (Papaemmanuil et 
al, 2013) were used to map the genomic landscape in 95 patients.  To enable 
comparisons with SES, genes were stratified into three functional groups based on 
the ability to regulate epigenetics, RNA splicing or transcriptional signalling (Bejar 
and Steensma, 2014). 
 
Cause of death 
The cause of death was determined from the final progress note by a hospital-
based or community physician.  In patients with transformed AML not in remission, 
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AML was identified as the cause of death.  Death associated with progressive 
cytopenias in the absence of circulating blasts, or cachexia was attributed to MDS.  
Infections as a cause of death included pneumonia as well as non-pneumonic, 
systemic sepsis.  Patients dying in hospital following surgery were classed as 
having died of post-surgical complications.  Patients older than 80 years, with 
stable blood counts who experienced sudden death were categorised as having 
died of ageing. 
To investigate associations with SES, causes of death were categorised 
into those arising as a complication of marrow dysfunction (including pneumonia, 
infection, bleeding, AML or progressive MDS) or organ failure (cardiac, renal or 
pulmonary disease).  In addition, death due to advanced age, other malignancies, 
post-surgery, thrombosis, post-operative or unknown causes constituted an 
‘ancillary’ category. 
 
Socioeconomic deprivation data 
The SES was inferred from the datazone associated with the patient’s residence 
postcode at the time of diagnosis and the Scottish Index of Multiple Deprivation 
(SIMD 2009).  SIMD is the Scottish Government's official tool for quantifying 
relative deprivation in Scotland.  The tool incorporates several different aspects of 
deprivation, based on employment, income, health, education, skills and training, 
geographic access to services, crime and housing and combines these into a 
single index.  Data were derived from the publically available database 
(http://www.scotland.gov.uk/Topics/Statistics/SIMD/SIMDPostcodeLookup/Scotlan
dPostcodeLookup).  Indices were assigned to quintile categorical indicators 
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ranked from SES1 (lowest) to SES5 (highest).  SES for patients diagnosed in the 
period prior to the development of the SIMD tool was calculated from the Carstairs 
index (http://www.isdscotland.org/products-and-Services/GPD-
Support/deprivation/carstairs/; Carstairs & Morris, 1990) and assigned to quintiles.  
Although the Carstairs index uses different criteria, Carstairs SES quintiles ranked 
from 1 (highest) to 5 (lowest) correlated negatively with those developed using 
SIMD (p<0.0001) suggesting the ability to identify similar SES groups.  For this 
reason, and likely absence of significant changes in post code-affiliated SES over 
the time period of the study-patient population, the SIMD 2009 tool was 
extrapolated to measure area SES in all patients. 
Statistical analysis 
The potential association between SES and co-variates included in the study: 
patient demographics (age and gender), clinicopathological characteristics 
(morphological sub-type of MDS, karyotype, genomic analysis and IPSS) and 
treatment details was investigated using the Chi Square test.  All statistical 
analysis was performed using R software (Version 3.2).  In addition, differences in 
patient outcomes including AML transformation, overall and leukaemia-free 
survival and causes of death were compared between SES quintiles.  Overall 
survival (OS) was measured as the time from diagnosis to the time of death or last 
follow-up; leukaemia-free survival (LFS) was calculated from the times between 
the diagnosis of MDS and AML diagnosis or time of last follow-up.  Survival 
outcomes were analysed using the log-rank test for Kaplan Meier survival curves.  
Cox regression models were used to estimate the hazard ratio for the significant 
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co-variates of both OS and LFS.  All p-values were two-tailed and statistical 
significance was set at the level of p< 0.05. 
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Results 
Patient demographics and disease characteristics (Table I) 
Of 305 patients in the registry, 283 Tayside residents were identified as being 
suitable for the study.  Ten local patients were excluded due to insufficient 
information including absence of marrow examination or failed cytogenetic analysis.  
The median age of patients in the final cohort was 76 years (range 28-97) with 163 
males and 120 females (ratio 1.3:1.  The number of patients in SES quintiles 1-5 was 
44 (15%), 57 (20%), 53 (19%), 84 (30%) and 45 (16%) respectively. 
MDS sub-types included RA (n=94), RARS (n=36), RCMD (n=39), RAEB 
(n=40), CMML (n=55) and MDS with 5q- (n=5).  Disease with fibrosis (n=5) and 
hypoplasia (n=4), and those with unclassifiable/proliferative disease (n=5) formed a 
miscellaneous group (n=14).  Nine patients had therapy-related MDS.  Good, 
intermediate or poor karyotype was identified in 217, 28 and 38 patients respectively. 
The IPSS was used to predict low (n=127), intermediate-1 (n=104), intermediate-2 
(n=43) or high-risk (n=9) disease.  By combining numbers of patients with low and 
intermediate-1 IPSS scores, 231 patients were classed as having lower-risk MDS; 
the remainder of the patients with intermediate-2 and high-risk MDS had higher-risk 
disease (n=52).  In the 95 patients who underwent genomic analysis, a total of 198 
mutations were identified with commonly mutated oncogenes including TET2 (22% 
of total mutations), SF3B1 (15%), SFRS2 (11%) and ASXL1 (10%).  Mutations in 
U2AF1, DNAMT3A, CBL, RUNX1, EZH2, TP53 and ZRZR2 accounted for 3-6%, 
NRAS, IDH1, KRAS, PHF6, STAG2, CUX1, EP300 and IDH2, 1-2% and BCOR, 
CEBPA, GATA2, JAK2, KIT, NF1, PTPN11 and RAD21 for <1% of the mutational 
spectrum. 
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Treatment (Table II) 
The majority of patients (n=257) exclusively received best supportive care (BSC) 
with blood products and antibiotics for treatment of infections.  In 26 patients, 
disease modifying therapy was used and 4 patients underwent allogeneic stem cell 
transplantation. 
Transformation to AML and the cause of death 
Transformation to AML was observed in 53 patients (19%), with the likelihood being 
greater in higher-risk MDS (21/52) than with lower-risk disease (32/231, X-squared 
15.54, df=1, 95% CI for the difference between proportions of transformation 12-40, 
p<0.0001). 
At last follow-up, 247 out of 283 patients (87%) had died.  Leukaemic-
transformation was the most frequent cause of death (22%) in the entire cohort 
followed by infection (20%) and advanced age (15%).  When the causes of death in 
patients with lower-risk MDS were examined (Table III), 17% of deaths in this sub-
group were related to leukaemic-transformation.  Death due to infection including 
pneumonia (20%), advanced age (16%), progressive MDS (8%), bleeding (7%), non-
myeloid malignancies (7%) and cardiac failure (6%) also accounting for fatalities 
(Table III).  In higher-risk MDS, death occurred due to leukaemic-transformation 
(38%), infection (25%), advanced age (11%), bleeding (4%) or progressive MDS 
(4%). 
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SES, MDS phenotype, genomic changes and prognostic scores (Table IV) 
To investigate the association between SES and MDS characteristics at diagnosis, 
patient demographics and clinicopathological variables within different SES quintiles 
were compared.  As shown in Table IV, there was no association between SES and 
age (X-squared 2.5, df=4, p=0.63) or gender (X-squared=2.4, df=4, p=0.67).  A 
statistical comparison of MDS sub-types and different SES groups was limited by 
small numbers in some MDS sub-groups.  We therefore investigated whether a 
diagnosis of RA compared to other forms of MDS (non-RA MDS) associated with 
SES, since the absence of excess blasts, uni-lineage cytopenia and dysplasia can 
make the diagnosis of RA more challenging than other MDS sub-types (Schiffer, 
2006; Malcovati et al, 2013).  By Chi-square test, a significant association between 
RA and SES was detected (X-squared=11.16, df=4, p=0.024).  Using ordinal 
regression modelling for the relation between SES and RA, the odds ratio of a 
diagnosis of RA was almost double that of non-RA in SES5 compared to other SES 
groups (odds ratio 1.9, CI 1.2-2.9; p=0.024). 
There was no significant association between SES and bone marrow 
karyotype (X-squared=5.3, df=8, p=0.72) or in sub-analysis (n=95) or the frequency 
of driver mutations in genes regulating epigenetics, RNA splicing or transcription (X-
squared=1.4, df=8, p=0.99).  The IPSS score too did not associate with SES, with 
lower- and higher risk-groups featuring equally in different SES quintiles (X-
squared=6.0482, df=4, p=0.19). 
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SES, treatment and disease outcomes 
Disease modifying therapy for lower-risk MDS was offered to 1, 0, 2, 4 and 6 patients 
in SES quintiles 1-5 respectively; corresponding patient numbers treated for higher-
risk MDS were 4, 4, 2, 2 and 1 respectively.  These numbers limited a statistically 
valid investigation of an association between SES and therapy.  No association was 
observed between SES and leukaemic-transformation (X-squared=2.63, df=4, 
p=0.62) or the cause of death (X-squared=6.49, df=8, p=0.59) (Table IV). 
Median survival of the entire cohort was 28.5 months (95% CI 24.6% -35.0%, range, 
0.10-280) (Figure 1A).  In a log-rank test of OS, age >70 years (p=0.006), higher-risk 
MDS (p<0.0001), male gender (p=0.022) and transformation to AML (p=0.0003) 
significantly decreased OS.  Multiple Cox regression models were fitted for the co-
variates from the univariate analysis and identified male gender (HR 1.3, 95% CI 1.0-
1.7, p=0.04), lower-risk disease (HR 0.38, 95% CI 0.27-0.53, p<0.0001, Figure 1B), 
age ≤70 years (HR 0.59, 95% CI 0.44-0.80, p=0.0007) and AML transformation (HR 
1.35, 95% CI 0.97-1.99, p=0.07) as being independent predictors of OS.  SES had 
not influence the OS of the entire cohort (p=0.37) or of patients with lower-risk 
(Figure 1C) and higher-risk MDS (Figure 1D). 
The median LFS was 27.9 months (95% CI 23.6-34.1, range (0.1-199).  As 
with OS, log-rank test indicated the importance of age >70 years (p<0.009), MDS 
risk-group (p<0.0001) and male gender (p=0.02) on LFS with no influence of SES 
(p=0.77).  Cox regression models further confirmed MDS risk-group (HR 0.3, 95% CI 
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0.21-0.41, p<0.0001, Figure 1C and D), male (HR 1.29, 95% CI 0.99-1.67 p=.051) 
and age (HR 0.61, 95% CI 0.45-0.83, p=0.02) as independent predictors of LFS. 
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Discussion 
Based on the established SES-dependent variation in clinicopathological 
characteristics and outcomes in many diseases (Barker, 1981; Gomez et al, 2015; 
Stringhini et al, 2013) including cancer (DeSantis et al, 2011; Kolahdooz et al, 2014; 
Lyratzopoulos et al, 2012; Roberts et al, 2015; Rutherford et al, 2013), we 
hypothesised a role for SES in influencing the biological and clinical heterogeneity in 
patients with MDS.  In previous studies, Wang et al (2009) investigated the 
prognostic role of neighbourhood SES in MDS using data from the Surveillance, 
Epidemiology and End Results (SEER) cancer registries linked to the national 
insurance programme Medicare in the USA and identified poorer survival in patients 
belonging to lower SES groups.  While this epidemiological study included a large 
number of patients, its relevance to areas with alternative mechanisms of health 
funding is unclear since affordability of therapy can confound interpretation of 
socioeconomic influences on cancer outcomes.  The predictors of survival we have 
identified in Cox-regression analyses are not new, but importantly, these validate our 
dataset and its suitability for models to investigate associations between SES and 
MDS.  Thus, the comparable survival outcomes between patients from different SES 
in our study, combined with the observations from a Canadian cohort of patients 
(England et al, 2013) strongly indicate the ability of equitable healthcare access in 
MDS to negate adverse outcomes associated with socioeconomic deprivation (Wang 
et al, 2009). 
When specific outcomes were studied, in contrast to the study by England et 
al, (2013), we were unable to demonstrate leukaemic-transformation as being more 
frequent in patients of higher SES.  Since all MDS patients in Tayside are treated 
within NHS Tayside hospitals, the possibility of referral patterns introducing bias in 
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the Canadian study should be considered.  We also failed to identify a contributory 
role for SES in influencing mortality patterns in both lower and higher risk MDS.  In 
particular, cardiovascular mortality, known to associate inversely with socioeconomic 
deprivation (Ramsay et al, 2015) was low (Dayyani et al, 2010) and equally 
represented in the SES quintiles.  Since cardiovascular deaths in MDS patients raise 
concerns about transfusion-associated iron overload, it would be important to state 
that barring one patient, the others had significant cardiovascular and valvular 
disease at the time of MDS diagnosis.  Unfortunately, data on co-morbidity on all 283 
patients in our cohort was not available, preventing a comprehensive evaluation of 
its association with SES and contribution to choice of therapy and outcomes. 
However, the analysis of co-morbidity in a subset of higher-risk patients included in a 
previous study (Durairaj et al, 2013) did not identify any obvious differences in co-
morbidity patterns between SES quintiles. 
When the morphological MDS sub-type was related to SES, uniquely, RA was 
more frequently diagnosed in patients from higher SES.  Since a diagnosis of RA 
relative to other MDS phenotypes can often be challenging, it is possible that some 
patients classed as having RA may not have had true MDS.  However, RA patients 
who were screened for driver mutations all had detectable genomic lesions, 
validating the morphological diagnosis of RA.  Relevant to the possible association of 
morphological sub-type of MDS with SES, a case-control study from China has 
suggested that the MDS phenotype can be influenced by occupation, life-style and 
educational status (generally associated with specific socioeconomic groups), with 
tobacco smoking, exposure to agricultural chemicals and lower educational 
achievements associating with RCMD and RAEB (Lv et al, 2011).  However, the 
frequency of MDS sub-types by morphology in the Chinese population is not 
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comparable to that in the West, referral and reporting bias may have skewed Lv et 
al’s study and a clear environmental pre-disposition is absent in an overwhelming 
majority of MDS patients (Bowen, 2013).  Additional studies would be helpful to 
confirm the association between morphological sub-types of MDS and SES. 
In keeping with observations from other studies (Wang et al, 2009; England et 
al, 2013), no cytogenetic features or MDS risk scores are unique to patients within 
specific SES quintiles.  Oncogenic gene mutations believed to drive the disease 
process in MDS also do not have an obvious association with SES when genes are 
grouped according to function: mutations in genes responsible for RNA splicing, 
regulation of the epigenome or transcription were equally represented in patients 
from different SES.  In breast cancer, it has been suggested that TP53 mutations 
may be over-represented in women facing extreme socioeconomic deprivation 
(Baker et al, 2010; Starks et al, 2013).  The absence of an obvious genomic link with 
SES in MDS here could reflect the existence of associations that are unique to a 
particular malignancy, limited patient numbers or differences in study criteria and 
analytical models. 
The decision to use the SIMD tool to identify area SES and assign SES 
warrants comment since criteria used to calculate SES often differ between studies.  
The assigning of any given deprivation score is derived from a person’s social 
characteristics.  Thus, information gathered by census, questionnaires or descriptive 
accounts can all be used to categorise people into ranks of most to least deprived. 
The SIMD tool uses location as an indicator of deprivation, assuming that people 
living in the same area (postcode-derived datazones) have broadly similar social 
circumstances.  By using data from seven domains relating to multiple aspects of 
life, an index that helps create the fullest possible picture of deprivation across 
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Scotland is generated.  The SIMD thus provides a means of analysing deprivation 
using a national reference.  Other tools such as the Carstairs index (Carstairs & 
Morris, 1990) are often used in similar studies, but this was deemed unsuitable due 
to the limited data available for the time-periods encompassed by this study. 
However, for patients whose date of diagnosis permitted an evaluation of deprivation 
using both the SIMD and Carstairs tools, the SES score based on the Carstairs 
index was comparable to SIMD data, indicating the applicability of the SIMD tool to 
historic patients.  SIMD 2009 was chosen for this study as this version of the SIMD 
tool reflected best the time period in which most patients in the study cohort had 
been diagnosed. 
A limitation of our study is the absence of data on historic area SES in 
individual patients since a comprehensive analysis of SES and MDS biology and 
phenotype would mandate the identification of deprivation most representative of a 
patient’s socio-economic history prior to the diagnosis of MDS.  The challenges 
posed by a review of each patient’s social history and mobility meant that the 
patient’s postcode at the time of diagnosis became a surrogate for lifetime location. 
Therefore the SIMD index will not reflect social mobility, or account for potential 
anomalies in deprivation within datazones.  It is unlikely that standardised patient 
datasets that include detailed biological variables, on which assessment tools that 
uniformly assess life-time patient SES in different populations will ever be developed. 
Thus, while our study has some limitations, it does succeed in establishing the 
absence of SES influences on MDS outcomes in a health-system providing equitable 
care, at least in patients exclusively receiving supportive treatments.  Whether 
potentially modifiable, environmental risk factors influence outcomes in MDS patients 
on therapy remain of interest. 
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Table I.  Patient demographics and clinicopathological variables (n=283). 
Variable Total 
Age (years) 
≤70 73 
>70 210 
Gender 
Males 163 
Females 120 
MDS Sub-type 
RA 94 
RARS 36 
RCMD 39 
RAEB 40 
CMML 55 
5q- 5 
Miscellaneous 14 
Karyotype 
Good 217 
Intermediate 28 
Poor 38 
Driver mutations 
Epigenetic 85 
RNA splicing 70 
Miscellaneous 43 
IPSS score 
Lower-risk 231 
Higher-risk 52 
SES 
Quintile 1 44 
Quintile 2 57 
Quintile 3 53 
Quintile 4 84 
Quintile 5 45 
Treatment 
Exclusive BSC 257 
Other 26 
AML transformation 53 
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Table II.  Therapies used in managing MDS patients. 
Therapy Patient number 
Exclusive best supportive care 257 
Danazol 3 
Erythropoietin+/- G-CSF 3 
Anti-lymphocyte globulin +/- Cyclosporin 4 
Low-dose chemotherapy 5 
Intensive chemotherapy 9 
Amifostine 1 
Lenalidomide 1 
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Table III.  Causes of death in lower-risk MDS. 
Cause of death Number (% of total deaths) 
Marrow dysfunction 
End-stage MDS 15 (8) 
AML 33 (17) 
Infection 15 (8) 
Pneumonia 23 (12) 
Bleeding 14 (7) 
Organ failure 
Cardiac failure 11 (6) 
Pulmonary disease 4 (2) 
Renal failure 6 (3) 
Ancillary 
Age 32 (16) 
Other malignancies 14 (7) 
Post-operative 5 (2.5) 
Thrombosis 5 (2.5) 
Misc. 8 (4) 
Not known 10 (5) 
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Table IV.  Association between SES and clinicopathological variables at diagnosis, 
prognostic scores, therapy and leukaemic-transformation in MDS. 
SES1 SES2 SES3 SES4 SES5 p 
Age (years) 0.63 
≤70 15 14 15 19 10 
>70 29 43 38 65 35 
Gender 0.67 
Males 25 31 27 53 27 
Females 19 26 26 31 18 
Sub-type 0.024* 
RA 7 18 19 28 22 
Non-RA MDS 37 39 34 56 23 
Karyotype 0.72 
Good 34 41 41 66 35 
Intermediate 4 5 4 8 7 
Poor 6 11 8 10 3 
Driver mutations 0.99 
Epigenetic 16 16 14 26 13 
RNA splicing 12 16 12 19 11 
Miscellaneous 9 11 6 11 6 
IPSS score 0.19 
Lower-risk 33 43 43 75 37 
Higher-risk 11 14 10 9 8 
Treatment 0.78 
BSC 39 53 49 77 39 
Other 5 4 4 7 6 
AML transformation 9 10 12 13 9 0.62 
Cause of Death 0.59 
Marrow dysfunction 20 25 35 38 20 
Organ failure 4 6 3 8 3 
Ancillary 15 19 11 26 14 
*Patient numbers in individual MDS sub-types within SES quintiles limited a
comparative analysis of SES and MDS sub-type, but a significant association 
between RA and SES was observed compared to non-RA MDS (OR 1.9, p=0.024). 
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Fig. 1.  Kaplan Meier survival curves in MDS patients.  Overall survival (OS) for the 
entire cohort (n=283) (A).  OS in with lower-risk MDS was superior (p<0.0001) to 
those with OS higher-risk disease (B).  No association between SES and OS was 
evident in patients with lower-risk (C) or higher-risk MDS (D). 


